Tags

Type your tag names separated by a space and hit enter

New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application.
J Pharmacol Sci. 2004 Dec; 96(4):362-6.JP

Abstract

Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of marijuana, induces catalepsy-like immobilization and impairment of spatial memory in rats. Delta9-THC also induces aggressive behavior in isolated housing stress. These abnormal behaviors could be counteracted by SR141716A, a CB1 cannabinoid receptor antagonist. Also Delta9-THC inhibited release of glutamate in the dorsal hippocampus, but this inhibition could be antagonized by SR141716A in an in vivo microdialysis study. Moreover, NMDA and AMPA-type glutamate receptor enhancers improved the Delta9-THC-induced impairment of spatial memory. On the other hand, Delta9-THC markedly inhibited the neurodegeneration in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis and reduced the elevated glutamate level of cerebrospinal fluid induced by EAE. These therapeutic effects on EAE were reversed by SR141716A. Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Delta9-THC-induced impairment of spatial memory, and the therapeutic effect of Delta9-THC on EAE, and a Delta9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases.

Authors+Show Affiliations

Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan. mfuji@fukuoka-u.ac.jpNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15599103

Citation

Fujiwara, Michihiro, and Nobuaki Egashira. "New Perspectives in the Studies On Endocannabinoid and Cannabis: Abnormal Behaviors Associate With CB1 Cannabinoid Receptor and Development of Therapeutic Application." Journal of Pharmacological Sciences, vol. 96, no. 4, 2004, pp. 362-6.
Fujiwara M, Egashira N. New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. J Pharmacol Sci. 2004;96(4):362-6.
Fujiwara, M., & Egashira, N. (2004). New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. Journal of Pharmacological Sciences, 96(4), 362-6.
Fujiwara M, Egashira N. New Perspectives in the Studies On Endocannabinoid and Cannabis: Abnormal Behaviors Associate With CB1 Cannabinoid Receptor and Development of Therapeutic Application. J Pharmacol Sci. 2004;96(4):362-6. PubMed PMID: 15599103.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. AU - Fujiwara,Michihiro, AU - Egashira,Nobuaki, Y1 - 2004/12/10/ PY - 2004/12/16/pubmed PY - 2005/4/29/medline PY - 2004/12/16/entrez SP - 362 EP - 6 JF - Journal of pharmacological sciences JO - J Pharmacol Sci VL - 96 IS - 4 N2 - Delta9-tetrahydrocannabinol (Delta9-THC), the major psychoactive component of marijuana, induces catalepsy-like immobilization and impairment of spatial memory in rats. Delta9-THC also induces aggressive behavior in isolated housing stress. These abnormal behaviors could be counteracted by SR141716A, a CB1 cannabinoid receptor antagonist. Also Delta9-THC inhibited release of glutamate in the dorsal hippocampus, but this inhibition could be antagonized by SR141716A in an in vivo microdialysis study. Moreover, NMDA and AMPA-type glutamate receptor enhancers improved the Delta9-THC-induced impairment of spatial memory. On the other hand, Delta9-THC markedly inhibited the neurodegeneration in experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis and reduced the elevated glutamate level of cerebrospinal fluid induced by EAE. These therapeutic effects on EAE were reversed by SR141716A. Taken together, our results demonstrate that the inhibition of glutamate release via activation of the CB1-cannabinoid receptor is one mechanism involved in Delta9-THC-induced impairment of spatial memory, and the therapeutic effect of Delta9-THC on EAE, and a Delta9-THC analog might provide an effective treatment for psychosis and neurodegenerative diseases. SN - 1347-8613 UR - https://www.unboundmedicine.com/medline/citation/15599103/New_perspectives_in_the_studies_on_endocannabinoid_and_cannabis:_abnormal_behaviors_associate_with_CB1_cannabinoid_receptor_and_development_of_therapeutic_application_ L2 - https://linkinghub.elsevier.com/retrieve/pii/JST.JSTAGE/jphs/FMJ04003X2 DB - PRIME DP - Unbound Medicine ER -